natgillin/translations-raw huggingface dataset:
End of IV Therapy (1º endpoint) Candidaemia only Other sterile sites Peritoneal fluid/IA c abscess 
Konec intravenskega zdravljenja (primarni opazovani dogodek) Samo kandidemija Druga sterilna mesta Peritonealna tekočina/IA
EUCAST has not determined non-species related breakpoints for anidulafungin 
Odbor EUCAST ni določil mejnih vrednosti za anidulafungin, neodvisnih od vrste.
The concentration of anidulafungin in the brain was low (brain to plasma ratio of approximately 0.2) in uninfected adult and neonatal rats after a single dose. 
Koncentracija anidulafungina v možganih pri neokuženih odraslih in novorojenih podganah je bila po enkratnem odmerku nizka (razmerje možgani/plazma približno 0,2).
Infusion-related adverse events are infrequent when the rate of anidulafungin infusion does not exceed 1.1 mg/min (see section 4.8). 
Z infundiranjem povezani neželeni učinku so redki, če hitrost infundiranja anidulafungina ne preseže 1,1 mg/minuto (glejte poglavje 4.8).
Anaphylactic reactions, including shock, were reported with the use of anidulafungin. 
Pri uporabi anidulafungina so poročali o anafilaktičnih reakcijah, vključno s šokom.
The rate of infusion should not exceed 1.1 mg/min (equivalent to 1.4 mL/min when reconstituted and diluted per instructions). 
Hitrost infuzije ne sme presegati 1,1 mg/min (kar ustreza 1,4 ml/min po rekonstituciji in ustreznem redčenju).
ECALTA contains fructose 
Zdravilo ECALTA vsebuje fruktozo
Dilution requirements for ECALTA administration 
Razredčenji za aplikacijo zdravila ECALTA
- Low blood potassium (hypokalaemia) - Diarrhoea - Nausea 
- nizka raven kalija v krvi (hipokaliemija) - driska - slabost s siljenjem na bruhanje
Infusion volume 
Infuzijski volumen A
- The active substance is anidulafungin. 
- Učinkovina je anidulafungin.
Excipients: fructose, mannitol, polysorbate 80, tartaric acid, NaOH and/or HCl. 
Pomožne snovi: fruktoza, manitol, polisorbat 80, vinska kislina, natrijev hidroksid in/ali klorovodikova kislina.
The infusion solution may be stored at 25°C (room temperature) for 48 hours or stored frozen for at least 72 hours, and should be administered at 25C (room temperature) within 48 hours. 
Raztopino za infundiranje lahko hranite do 48 ur pri temperaturi 25 C (sobna temperatura) ali pa jo hranite zamrznjeno najmanj 72 ur.
If either particulate matter or discolouration are identified, discard the solution. 
Če ugotovite prisotnost delcev ali obarvanje, morate raztopino zavreči.
The most common pathogens isolated from a deep tissue site at baseline were C. albicans (64.3%; 83 of 129), C. glabrata (31.0%; 40 of 129), C. tropicalis (11.6%; 15 of 129), and C. krusei (5.4%; 7 of 129). 
Najpogosteje izolirani patogeni iz globokega tkiva ob izhodišču so bili C. albicans (64,3 %; 83 od 129), C. glabrata (31,0 %; 40 od 129), C. tropicalis (11,6 %; 15 od 129) in C. krusei (5,4 %; 7 od 129).
Either 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/mL (5%) glucose for infusion. 
Bodisi natrijev klorid 9 mg/ml (0,9 %) za infundiranje bodisi glukoza 50 mg/ml (5 %) za infundiranje.
Aseptically transfer the contents of the reconstituted vial(s) into an intravenous bag (or bottle) containing either 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/mL (5%) glucose for infusion obtaining an anidulafungin concentration of 0.77 mg/mL. 
Aseptično prenesite vsebino rekonstituirane viale/rekonstituiranih vial v intravensko vrečko (ali steklenico), ki vsebuje bodisi natrijev klorid 9 mg/ml (0,9 %) za infundiranje bodisi glukozo 50 mg/ml (5 %) za infundiranje, da boste dobili koncentracijo anidulafungina 0,77 mg/ml.
Hypotension, hypertension 
Žilne bolezni hipotenzija, hipertenzija pordevanje, vročinski oblivi
The successful global response rate at the End of Intravenous Treatment (primary endpoint) was 18/35 (51.4%) and 16/35 (45.7%) at the End of All Treatment. 
18/35 (51,4 %), na koncu celotnega zdravljenja pa 16/35 (45,7 %).
ECALTA is not dialysable. 
Zdravila ECALTA z dializo ni mogoče odstraniti.
What ECALTA contains 
Kaj vsebuje zdravilo ECALTA
In clinically stable patients, a switch to oral azole therapy was permitted after at least 5 to 10 days of treatment with anidulafungin. 
Klinično stabilni bolniki so lahko po vsaj 5 do 10 dneh zdravljenja z anidulafunginom prešli na peroralno zdravljenje z azoli.
The efficacy of anidulafungin (200 mg intravenous loading dose followed by 100 mg intravenous daily) was assessed in 35 adult neutropenic patients defined as absolute neutrophil count ≤ 500 cells/mm 
Učinkovitost anidulafungina (200 mg intravenski polnilni odmerek, ki mu je sledila aplikacija 100 mg intravensko na dan) so ocenili pri 35 odraslih nevtropeničnih bolnikih, opredeljenih z absolutnim številom nevtrofilcev ≤ 500 celic/mm
Life-threatening allergic reactions that might include difficulty breathing with wheezing or worsening of an existing rash have been rarely reported during administration of ECALTA. 
Pri uporabi zdravila ECALTA so redko poročali o življenjsko ogrožajočih alergijskih reakcijah, ki lahko vključujejo oteženo dihanje s piskanjem ali poslabšanje že obstoječega izpuščaja.
Anidulafungin is not hepatically metabolised. 
Anidulafungin se ne presnavlja v jetrih.
ECALTA can be given without regard to the timing of haemodialysis (see section 5.2). 
Zdravilo ECALTA lahko apliciramo ne glede na čas hemodialize (glejte poglavje
The efficacy of anidulafungin (200 mg intravenous loading dose followed by 100 mg intravenous daily) in adult neutropenic patients (defined as absolute neutrophil count ≤ 500 cells/mm 
Učinkovitost anidulafungina (200 mg intravenski polnilni odmerek, ki mu je sledila aplikacija 100 mg intravensko na dan) pri odraslih nevtropeničnih bolnikih (opredeljenih z absolutnim številom nevtrofilcev ≤ 500 celic/mm
It is recommended that ECALTA be administered at a rate of infusion that does not exceed 1.1 mg/min (equivalent to 1.4 mL/min when reconstituted and diluted per instructions). 
Priporočljivo je, da hitrost infundiranja zdravila ECALTA ne preseže 1,1 mg/minuto (kar ustreza 1,4 ml/minuto po rekonstituciji in ustreznem redčenju).
The compatibility of reconstituted ECALTA with intravenous substances, additives, or medicines other than 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/mL (5%) glucose for infusion has not been established. 
Združljivost rekonstituiranega zdravila ECALTA z intravenskimi snovmi, aditivi ali zdravili razen 9 mg/ml (0,9 %) natrijevega klorida za infundiranje ali 50 mg/ml (5 %) glukoze za infundiranje ni ugotovljena.
In the 4 open-label studies, a switch to oral azole therapy was permitted after at least 5 to 10 days of treatment with anidulafungin. 
V 4 odprtih preskušanjih so lahko klinično stabilni bolniki po vsaj 5 do 10 dneh zdravljenja z anidulafunginom prešli na peroralno zdravljenje z azoli.
Patients with renal and hepatic impairment 
Bolniki z okvaro ledvic ali jeter
In clinically stable patients, a switch to oral azole therapy was permitted after at least 10 days of study treatment. 
Klinično stabilni bolniki so lahko po vsaj 10 dneh zdravljenja s preskušanim zdravilom prešli na peroralno zdravljenje z azoli.
Anaphylacti c shock, anaphylactic reaction* 
Bolezni imunskega sistema anafilaktičn i šok, anafilaktičn a reakcija*
Common side effects (may affect up to 1 in 10 people) are: 
Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov) so:
ECALTA 100 mg powder for concentrate for solution for infusion 
ECALTA 100 mg prašek za koncentrat za raztopino za infundiranje
C) anidulafungin (~88 mg) was administered to healthy subjects. 
V kliničnem preskušanju posamičnega odmerka so zdravim preskušancem dali radioaktivno označen C) anidulafungin (~88 mg).
In some patients with serious underlying medical conditions who were receiving multiple concomitant medicines along with anidulafungin, clinically significant hepatic abnormalities have occurred. 
Klinično pomembne jetrne nenormalnosti so se pojavile pri nekaterih bolnikih z resnimi osnovnimi boleznimi, ki so sočasno z anidulafunginom dobivali več zdravil.
Table of Adverse Reactions System Organ 
Preglednica neželenih učinkov Organski sistem Zelo pogosti
ECALTA 100 mg powder for concentrate for solution for infusion Anidulafungin 
ECALTA 100 mg prašek za koncentrat za raztopino za infundiranje anidulafungin
The solution should be inspected visually for particulate matter and discoloration prior to administration. 
Raztopino je treba pred uporabo vizualno pregledati, da ne vsebuje delcev in ni obarvana.
Common to 
Občasni do
General pharmacokinetic characteristics 
Splošne farmakokinetične značilnosti
6 Week Follow-up Calculated as anidulafungin minus fluconazole With or without concurrent candidaemia c 
Spremljanje po 6 tednih izračunano kot anidulafungin minus flukonazol s sočasno kandidemijo ali brez nje c intraabdominalni prikazani so podatki bolnikov z enim samim patogenom na začetku preskušanja e
Skin and Subcutaneous Tissue Disorders 
Bolezni kože in podkožja izpuščaj, pruritus urtikarija
Exacerbation of infusion-related reactions by co-administration of anaesthetics has been seen in a nonclinical (rat) study (see section 5.3). 
V neklinični študiji (na podganah) so zabeležili poslabšanje z infundiranjem povezanih reakcij med sočasno uporabo anestetikov (glejte poglavje 5.3).
The contents of the vial must be reconstituted with water for injections and subsequently diluted with ONLY 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/mL (5%) glucose for infusion. 
Vsebino viale morate rekonstituirati z vodo za injekcije in nato razredčiti SAMO z raztopino 9 mg/ml (0,9 %) natrijevega klorida za infundiranje ali raztopino 50 mg/ml (5 %) glukoze za infundiranje.
Patients were randomised to receive either anidulafungin (200 mg intravenous loading dose followed by 100 mg intravenous daily) or fluconazole (800 mg intravenous loading dose followed by 400 mg intravenous daily), and were stratified by APACHE II score (≤20 and >20) and the presence or absence of neutropaenia. 
Bolnike so randomizirali na prejemanje bodisi anidulafungina (200 mg intravenski polnilni odmerek, ki mu je sledila aplikacija po 100 mg na dan intravensko) bodisi flukonazola (800 mg intravenski polnilni odmerek, ki mu je sledila aplikacija po 400 mg na dan intravensko).
ECALTA must be reconstituted with water for injections and subsequently diluted with ONLY sodium chloride 9 mg/mL (0.9%) solution for injection or 50 mg/mL (5%) glucose for infusion. 
Zdravilo ECALTA morate rekonstituirati z vodo za injekcije in nato razredčiti SAMO z raztopino 9 mg/ml (0,9 %) natrijevega klorida za infundiranje ali raztopino 50 mg/ml (5 %) glukoze za infundiranje.
EUCAST Breakpoints 
Mejne vrednosti po odboru EUCAST
Sodium hydroxide (for pH-adjustment) Hydrochloric acid (for pH-adjustment) 
6.1 Seznam pomožnih snovi fruktoza manitol polisorbat 80 vinska kislina natrijev hidroksid (za prilagoditev pH) klorovodikova kislina (za prilagoditev pH)
Infusion solution 
Raztopina za infundiranje
The reconstituted solution may be stored up to 25°C for up to 24 hours prior to further dilution. 
Rekonstituirano raztopino lahko pred nadaljnjim redčenjem hranite do največ 24 ur pri temperaturi do največ 25 °C.
- If you get any side effects, talk to your doctor, or pharmacist or nurse. 
- Če opazite katerikoli neželeni učinek, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Respiratory, Thoracic and Mediastinal Disorders 
Bolezni dihal, prsnega koša in mediastinalnega prostora bronhospazem, dispneja
Parenterally administered anidulafungin was effective against Candida species in immunocompetent and immunocompromised mouse and rabbit models. 
Pri imunokompetentnih in imunsko oslabelih miših in kuncih je bil parenteralno aplicirani anidulafungin učinkovit proti vrstam Candida.
Powder for concentrate for solution for infusion 
1 viala prašek za koncentrat za raztopino za infundiranje
A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter. 
Prvi dan je treba aplicirati en sam 200 mg polnilni odmerek, potem pa po 100 mg na dan. Trajanje zdravljenja mora temeljiti na kliničnem odzivu bolnika.
After subsequent dilution, the solution is to be discarded if particulate matter or discoloration is identified. 
Če po nadaljnjem razredčenju ugotovite prisotnost delcev ali obarvanje, morate raztopino zavreči.
A successful global response was defined as both clinical and microbiologic success EOIVT, End of Intravenous Treatment; EOT, End of All Treatment 
EOIVT - konec intravenskega zdravljenja; EOT - konec celotnega zdravljenja
Hepatic metabolism of anidulafungin has not been observed. 
Presnove anidulafungina v jetrih niso opazili.
No dose limiting toxicity was observed in a study of 10 healthy subjects administered a loading dose of 260 mg followed by 130 mg daily; 3 of the 10 subjects experienced transient, asymptomatic transaminase elevations (3 x Upper Limit of Normal (ULN)). 
Pri 3 od 10 preskušancev se je pojavilo prehodno, asimptomatsko zvišanje transaminaz ( 3-kratna zgornja meja normale (ZMN)).
The reconstituted solution may be stored at up to 25°C for up to 24 hours. 
Rekonstituirana raztopina Rekonstituirano raztopino lahko hranite do največ 24 ur pri temperaturi do 25 °C.
Talk to your doctor or pharmacist or nurse before using ECALTA. 
Pred začetkom uporabe zdravila ECALTA se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
ECALTA 100 mg powder for concentrate for solution for infusion anidulafungin 
ECALTA 100 mg prašek za koncentrat za raztopino za infundiranje anidulafungin i.v.
Total infusion volume 
Celotna količina za infundiranjeB
Posology 
škatla
The reconstituted solution may be stored up to 25C for up to 24 hours. 
Rekonstituirano raztopino lahko hranite do največ 24 ur pri temperaturi do 25 C.
Insufficient evidence 
DRUGI PODATKI
The powder is white to off-white. 
Prašek bele do belkaste barve.
Rare to 
Pogosti do
Pleural cavity 
Okvara ledvic
Increased levels of hepatic enzymes have been seen in healthy subjects and patients treated with anidulafungin. 
Pri zdravih preskušancih in bolnikih, zdravljenih z anidulafunginom, so poročali o zvišanih ravneh jetrnih encimov.
How to store ECALTA 
Shranjevanje zdravila ECALTA
Patients with microbiologically confirmed invasive candidiasis (MITT population) and neutropenia were identified in an analysis of pooled data from 4 similarly designed prospective, open-label, noncomparative studies. 
V analizi združenih podatkov iz 4 prospektivnih, odprtih, neprimerjalnih preskušanj s podobnim načrtom so ocenili bolnike z mikrobiološko potrjeno invazivno kandidozo (populacija MITT) in nevtropenijo.
Ask your doctor or pharmacist for advice before taking ECALTA while breast-feeding. 
Preden v obdobju dojenja uporabite zdravilo ECALTA, se posvetujte z zdravnikom ali farmacevtom.
- if you are given anaesthetics during your treatment with ECALTA.for signs of an allergic reaction such as itching, wheezing, blotchy skin - for signs of an infusion-related reaction which could include a rash, hives, itching, redness, - for shortness of breath/breathing difficulties, dizziness or lightheadedness 
- glede znakov alergijske reakcije, kot so srbenje, piskajoče dihanje, lisasta koža.
Contact your doctor immediately if you become pregnant while taking ECALTA. 
Če med zdravljenjem z zdravilom ECALTA zanosite, se nemudoma posvetujte z zdravnikom.
Fructose 
c absces
Within 4 years after Commission decision 
V štirih letih po sklepu Komisije
Within 3 months after Commission decision 
V treh mesecih po sklepu Komisije
From the date of notification of the Commission Decision 
Od dneva obvestila o sklepu Komisije
Methotrexate-containing products for oral use with at least one indication requiring once weekly dosing Each MAH should operate a risk management system to be described in a risk management plan (RMP) which shall be submitted to the relevant Competent Authorities. 
Zdravila, ki vsebujejo metotreksat, za peroralno uporabo z vsaj eno indikacijo, ki zahteva odmerjanje enkrat na teden Vsi imetniki dovoljenj za promet z zdravilom morajo upravljati sistem za obvladovanje tveganja, ki ga je treba opisati v načrtu za obvladovanje tveganj (RMP), tega pa je treba predložiti zadevnim pristojnim organom.
The RMP should reflect the following additional risk minimisation measures to address the important identified risk of medication errors resulting in overdose: - educational material(s) for healthcare professionals developed in accordance with the key elements agreed; - the agreed patient card. 
Načrt za obvladovanje tveganj mora odražati naslednje ukrepe za zmanjšanje tveganja, ki obravnavajo pomembno ugotovljeno tveganje za napake pri uporabi zdravila, ki privedejo do prevelikega odmerjanja: - izobraževalna gradiva za zdravstvene delavce, pripravljena v skladu s ključnimi dogovorjenimi elementi; - dogovorjena bolnikova kartica.
All methotrexate-containing products Each MAH should implement the agreed targeted follow-up questionnaires for all medication errors resulting in overdose. 
Vsa zdravila, ki vsebujejo metotreksat Vsi imetniki dovoljenj za promet z zdravilom morajo uvesti dogovorjene vprašalnike za spremljanje vseh napak pri uporabi zdravila, ki privedejo do prevelikega odmerjanja.
MAHs should replace any bottle or tube used as immediate packaging by blisters. 
Pri formulacijah v obliki tablet je treba uvesti tudi naslednji ukrep: imetniki dovoljenj za promet z zdravilom morajo stekleničke ali epruvete, ki se uporabljajo kot stična ovojnina, nadomestiti s pretisnimi omoti.
Your doctor will decide which is best for you. 
Vaš zdravnik bo odločil, kaj je za vas najbolje.
· Risk Management plan (RMP) 
• Načrt za obvladovanje tveganja (RMP)
The recommended treatment duration is 6 weeks. 
Priporočen čas zdravljenja je 6 tednov.
It is unlikely to be serious. 
Zelo malo je verjetno, da bi to imelo resne posledice.
This multidose preparation can be used for several patients. 
Ta večodmerni pripravek lahko uporabimo za več bolnikov.
Please discuss this with your doctor. 
Prosimo, da se o tem pogovorite s svojim zdravnikom.
Other in-use storage times and conditions are the responsibility of the user. 
Drugačen čas shranjevanja raztopine in drugi pogoji shranjevanja so odgovornost uporabnika.
(See instruction for use at the end of this leaflet) 
(Glejte navodila na koncu tega navodila za uporabo.)
It needs to be treated at once. 
To reakcijo je treba takoj zdraviti.
· If you do not hear a click, look to see that the needle is fully covered by the safety shield. 
• Če ne slišite klika, poglejte, če je igla v celoti pokrita z varnostno zaščito.
Treatment must be started under the supervision of your doctor. 
Zdravljenje je treba začeti pod nadzorom zdravnika.
Poorly controlled hypertension. 
Slabo nadzorovana hipertenzija.
Make sure you always hold the syringe as shown in the picture below. 
Prepričajte se, da vedno držite brizgo, kot je prikazano na sliki.
In this case dose increases may be necessary. 
V tem primeru bodo morda potrebni večji odmerki.
Children will start by following the same guidelines. 
Otroci bodo začeli z zdravljenjem po enakih navodilih.
In this case, proceed to step 19 and contact your healthcare provider. 
V tem primeru nadaljujte s korakom 19 in se obrnite na zdravstvenega delavca.
Appropriate dose titration should be considered. 
Upoštevati je treba primerno titracijo odmerka.
These may be signs of severely elevated blood pressure (hypertensive crisis), even if your blood pressure is usually normal or low. 
To so lahko znaki zelo povišanega krvnega tlaka (hipertenzivne krize), čeprav je vaš krvni tlak običajno normalen ali nizek.
This is a multidose preparation from which different single doses can be withdrawn over a period of 1 month after dissolution. 
To je večodmerni pripravek, iz katerega lahko odvzamemo več enkratnih odmerkov v 1 mesecu po raztopitvi.
Your doctor will always record the exact product you are using. 
Zdravnik bo vedno zabeležil natančno tisto zdravilo, ki ga uporabljate.
8 Wash your hands with soap and water. 
8 Roke si umijte z milom in vodo.
The first dose is usually given to you under medical supervision, because of the possibility of an allergic reaction. 
Prvi odmerek boste prejeli pod zdravniškim nadzorom, ker obstaja možnost alergične reakcije.
(4) Replace the needle by a new one (the new needle should have the size which you normally use for injections). 
(4) Iglo zamenjajte z novo (nova igla naj ima tako velikost, kot jo običajno uporabljate za injekcije).
D-82377 Penzberg Germany 
D-82377 Penzberg Nemčija
Do not inject within 5 cm (2 inches) area directly around your belly button. 
Ne injicirajte v območju 5 cm (2 palcev) okoli popka.
(7) Hold the OPC (One-Point-Cut) ampoule with the blue point upwards. 
(7) Držite ampulo OPC (one point cut) z modro piko kvišku.
· Gently twist until it is fully attached (C) 
• Rahlo jo privijte, dokler ni popolnoma pritrjena (C).
· Do not speed up the warming process in any way, and do not put the syringe in a microwave or in warm water. 
• Na noben način ne pospešujte postopka ogrevanja in injekcijske brizge ne dajajte v mikrovalovno pečico ali v toplo vodo.
Your doctor will take regular blood samples. 
Zdravnik vam bo redno jemal vzorce krvi.
· Subcutaneous administration (under the skin). 
• subkutano dajanje (pod kožo).
Patients with cancer 
Bolniki z rakom
These reactions were usually mild to moderate and went away within a few hours or days. 
Te reakcije so bile večinoma blage do zmerne in so izginile po nekaj urah ali dneh.
In the absence of compatibility studies, this medicinal product should not be mixed with other medicinal products. 
Zaradi pomanjkanja študij kompatibilnosti zdravila ne smemo mešati z drugimi zdravili.
· If needed, you may cover the injection site with a small bandage. 
• Če je treba, lahko mesto injiciranja prekrijete z majhnim obližem.
Blood pressure monitoring 
Kontrola krvnega tlaka
Write the date of reconstitution and expiry on the label (expiry is 1 month after reconstitution). 
Na nalepko napišite datum priprave raztopine in rok uporabnosti (rok uporabnosti je 1 mesec po rekonstituciji).
1 Find a well-lighted, clean, flat, working surface. 
1 Poiščite dobro osvetljeno, čisto in ravno delovno površino.
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). 
Študije na živalih ne kažejo neposredne ali posredne škodljive vplive na nosečnost, razvoj zarodka/plodu, porod ali postnatalni razvoj (glejte poglavje 5.3).
Under no circumstances should more than one dose be administered per syringe; the medicinal product is for single use only. 
Pod nobenim pogojem ne smemo brizge uporabiti za več kot en odmerek; zdravilo je samo za enkratno uporabo.
Do not use glass materials for injection, use only plastic materials. 
Za injiciranje ne uporabljajte steklenih materialov, ampak samo plastične.
Epoetins are not approved in the management of anaemia associated with hepatitis C. 
Epoetini niso odobreni za zdravljenje anemije, povezane s hepatitisom C.
Subcutaneous and intravenous use. 
Subkutana in intravenska uporaba.
[units] 
(enote)
First wash your hands! 
Pred uporabo si skrbno umijte roke!
9 Select a vein. 
9 Izberite veno.
18 Move the safety shield forward 90°, away from the syringe barrel (A). 
18 Varnostno zaščito premaknite za 90° naprej, stran od valja injekcijske brizge (A).
This should avoid a blockage in the tubing of the dialysis system. 
To bo preprečilo zamašitev cevi dializnega sistema.
Your healthcare provider will show you how to prepare and inject NeoRecormon properly before you use it for the first time. 
Vaš zdravstveni delavec naj vam pokaže, kako pravilno pripraviti in injicirati zdravilo NeoRecormon, preden ga prvič uporabite.
Warnings and precautions 
Opozorila in previdnostni ukrepi:
However, in controlled clinical studies no increased incidence of hypersensitivity reactions was found. 
V nadzorovanih kliničnih študijah povečane incidence preobčutljivostnih reakcij niso opazili.
Epoetin beta is produced by a specialised genetic technology and works in exactly the same way as the natural hormone erythropoietin. 
Epoetin beta je pridobljen s specializirano genetsko tehnologijo in deluje popolnoma enako kakor naravni hormon eritropoetin.